A review of biosimilar in regulations and potential impact: Hong Kong perspectives

Click to increase image sizeClick to decrease image size

Transparency

Declaration of funding

This paper was not funded.

Declaration of financial/other interests

Both authors declare that they have no conflict of interests. One peer reviewer discloses that they are a shareholder in Matrix45, which has been contracted for work on biosimilars by Sandoz/Novartis, Teva, and Hospira/Pfizer. Per company policy, employees cannot contract individually with sponsor organizations and cannot hold equity in sponsor organizations. Another peer reviewer discloses that they have received research, speaking, and/or consulting support from a variety of companies, including Galderma, GSK/Stiefel, Almirall, Alvotech, Leo Pharma, BMS, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. This reviewer also consults for Guidepoint Global, Gerson Lehrman, and other consulting organizations, and they are the founder and majority owner of www.DrScore.com, as well as the founder and part owner of Causa Research. The peer reviewers on this manuscript have no other relevant financial or other relationships to disclose.

Acknowledgements

None reported.